NCT05294731 2026-04-17Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-DegraderBeOne MedicinesPhase 1/2 Recruiting146 enrolled
NCT05131022 2026-04-14A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesNurix Therapeutics, Inc.Phase 1 Recruiting572 enrolled
NCT06544265 2026-04-14SynKIR-310 for Relapsed/Refractory B-NHLVerismo TherapeuticsPhase 1 Recruiting36 enrolled
NCT07387471 2026-04-13Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)AbbViePhase 2 Recruiting14 enrolled
NCT04911478 2026-04-09Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T CellsAdicet TherapeuticsActive not recruiting50 enrolled
NCT04903197 2026-04-01Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin LymphomaNovartisPhase 1 Terminated18 enrolled
NCT06533579 2026-03-30Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)Vironexis Biotherapeutics Inc.Phase 1/2 Recruiting32 enrolled
NCT05753501 2026-03-27Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell MalignanciesAbbViePhase 1 Active not recruiting135 enrolled